496 related articles for article (PubMed ID: 28836341)
1. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
[TBL] [Abstract][Full Text] [Related]
2. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
Manco-Johnson MJ; Kempton CL; Reding MT; Lissitchkov T; Goranov S; Gercheva L; Rusen L; Ghinea M; Uscatescu V; Rescia V; Hong W
J Thromb Haemost; 2013 Jun; 11(6):1119-27. PubMed ID: 23528101
[TBL] [Abstract][Full Text] [Related]
5. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
[TBL] [Abstract][Full Text] [Related]
6. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
Olasupo OO; Lowe MS; Krishan A; Collins P; Iorio A; Matino D
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014201. PubMed ID: 34407214
[TBL] [Abstract][Full Text] [Related]
7. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.
Oldenburg J; Zimmermann R; Katsarou O; Theodossiades G; Zanon E; Niemann B; Kellermann E; Lundin B;
Haemophilia; 2015 Mar; 21(2):171-179. PubMed ID: 25470205
[TBL] [Abstract][Full Text] [Related]
8. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
[TBL] [Abstract][Full Text] [Related]
9. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.
Hilliard P; Zourikian N; Blanchette V; Chan A; Elliott B; Israels SJ; Nilson J; Poon MC; Laferriere N; Van Neste C; Jarock C; Wu J; McLimont M; Feldman B
J Thromb Haemost; 2013 Mar; 11(3):460-6. PubMed ID: 23301594
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Manco-Johnson MJ; Abshire TC; Shapiro AD; Riske B; Hacker MR; Kilcoyne R; Ingram JD; Manco-Johnson ML; Funk S; Jacobson L; Valentino LA; Hoots WK; Buchanan GR; DiMichele D; Recht M; Brown D; Leissinger C; Bleak S; Cohen A; Mathew P; Matsunaga A; Medeiros D; Nugent D; Thomas GA; Thompson AA; McRedmond K; Soucie JM; Austin H; Evatt BL
N Engl J Med; 2007 Aug; 357(6):535-44. PubMed ID: 17687129
[TBL] [Abstract][Full Text] [Related]
11. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease.
Hilgartner MW; Makipernaa A; Dimichele DM
Haemophilia; 2003 May; 9(3):261-8. PubMed ID: 12694515
[TBL] [Abstract][Full Text] [Related]
12. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
[TBL] [Abstract][Full Text] [Related]
13. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
[TBL] [Abstract][Full Text] [Related]
14. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
[TBL] [Abstract][Full Text] [Related]
15. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
Feldman BM; Pai M; Rivard GE; Israels S; Poon MC; Demers C; Robinson S; Luke KH; Wu JK; Gill K; Lillicrap D; Babyn P; McLimont M; Blanchette VS;
J Thromb Haemost; 2006 Jun; 4(6):1228-36. PubMed ID: 16706965
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
17. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
[TBL] [Abstract][Full Text] [Related]
19. SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data.
Hong W; Raunig D; Lundin B
Haemophilia; 2016 Nov; 22(6):e519-e526. PubMed ID: 27642172
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
